Under the Paperwork Reduction Act of 1995, no persons are required to resp

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT
(Not for submission under 37 CFR 1.99)

Application Number		10786752			
Filing Date		2004-02-25			
First Named Inventor Chris		topher E. Bales			
Art Unit		2171			
Examiner Name					
Attornov Docket Numb	ne.	DEAC 01272HO0			

					U.S.I	PATENTS			Remove		_
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date Name of Patentee or Applicant			Releva		Lines when ges or Relev		
	1	6738789	B2	2004-0	5-08	Multer et al.					
	2	6779002	B2	2004-0	8-17	Mwaura Skufca et al.					
	3	6922695	B2	2005-0	7-26						
	4	6934934	В1	2005-0	8-23	Osborne, II et	al.				
If you wis	h to a	dd additional U.S. Pater	t citatio	n inform	ation pl	ease click the	Add button.		Add		
			U.S.P	ATENT	APPLI	CATION PUBL	LICATIONS		Remove		
Examiner Initial*	Cite No	Publication Number	Kind Code ¹		Publication Name of Patentee or Applicant of cited Document			Releva		Lines where ges or Relev	
	1										
If you wis	h to a	d additional U.S. Public	shed Ap	plication	citation	n information p	lease click the Ad	d button	Add		_
				FOREIG	SN PAT	ENT DOCUM	ENTS		Remove		_
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ²		Kind Code4		Name of Patente Applicant of cited Document	e or V	vhere Rel	or Relevant	TS

	Application Number		10786752	
NEODMATION DIOCE COURT	Filing Date		2004-02-25	
INFORMATION DISCLOSURE	First Named Inventor Chris		stopher E. Bales	
STATEMENT BY APPLICANT Not for submission under 37 CFR 1.99)	Art Unit		2171	
Not for Submission and of or the 1.55y	Examiner Name			
	Attorney Docket Number		BEAS-01373US0	

	1									
If you wis	h to a	dd add	itional Fore	ign Pa	atent Document	citation	information pl	ease click the Add buttor	Add	
					NON-PATE	NT LITE	RATURE DO	CUMENTS	Remove	
Examiner Initials*	Examiner Cite Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.					Тs				
	1									
If you wis	If you wish to add additional non-patent literature document citation information please click the Add button Add									
	EXAMINER SIGNATURE									
Examiner	Signa	ture						Date Considered		

See Kint Codes of USPTO Patent Documents at Invent/ISPTO.GDV or MPEP 901.04. Enter office that issued the document, by the Nov-letter option Standard 513.) For Explanates patent of Lournets, the Indication of the year of the register precedes the sent number patent document. And occurrently the sportports symbols as endicated on the document under WIPO Standard 51.16 if possible. Sportcard is to place a check mark here if English language translation is attached.

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10786752
Filing Date		2004-02-25
First Named Inventor	Chris	topher E. Bales
Art Unit		2171
Examiner Name		
Attorney Docket Numb	er	BEAS-01373US0

CERTIFICATION STATEMENT

Please see 37	CFR 1.97	and 1.98	to make the	appropriate	selection(s):
---------------	----------	----------	-------------	-------------	---------------

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 3.7 CFR 1.97(eVI.)

OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no tem of Information contained in the information disclosure statement was known to [2] any individual designated in 37 CFR 1.58(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.59(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.59(c) more than three months prior to the filing of the information disclosure

See attached certification statement.

Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.

□ None

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/Joseph P. O'Malley/	Date (YYYY-MM-DD)	2006-08-18							
Name/Print	Joseph P. O'Malley	Registration Number	36226							

This collection of information is required by 3T CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is foll field and by the USPTO to process) an application. Confidentiality is governed by \$5 U.S. C.12 and 3T CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Tradenan's Afford, U.S. Department of Commence, P. 0. Bot 1450, Alexandria, V.32.511.450, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P. 0. Box 1450, Alexandria, V.32.311.450.

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, please be advised that (1) the general authority for the collection of this information is \$3 U.S.C. 2(b)(2); (2) famishing of the information solicided is voluntary, and (3) the principal purpose for which the information is used by the U.S. Patient and Trademan Kolline is to process and/or examine your submission related to a patient application or patient. If you do not furnish the requested process and/or examine your submission related to a patient application or patient. If you do not furnish the requested related to the patient of the patient application or patient. If you do not furnish the requested related to the patient process and/or examine your submission, which may related that the patient process and/or examine your submission, which may related that the patient process and/or examine your submission.

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
 - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement neodiations.
 - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record partains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
 - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974. as amended, pursuant to 5 U.S.C. 552a(m.).
 - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
 may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
 to the Patent Cooperation Treaty.
 - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
- 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designe, cuting an inspection of records concluded by GSAs and of that agency's responsibility to recommend improvements in records management practices and programs, under suthority of 4d U.S.C. 2004 and 2006. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 12(b) or issuance of a patient pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR.114, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application port to public insepticines or an issued patient.
 - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.